Literature DB >> 31937492

Seasonal variation of diabetes with hyperosmolarity hospitalizations and its characteristics in mainland Portugal.

Carlos Gomes1, Débora Fonseca2, Alberto Freitas3.   

Abstract

AIMS: The family physician devotes a part of his care to the surveillance of diabetic patients. Hyperosmolarity is a severe acute complication. The aim of this study was to analyse seasonal variation of type 2 diabetes with hyperosmolarity hospitalizations, regarding their occurrence, mortality, length of stay, Charlson comorbidity index and its factors.
METHODS: The authors analysed all hospitalizations in Portuguese Mainland public sector hospitals between 2000 and 2015 with primary diagnosis of type 2 diabetes with hyperosmolarity (ICD-9-CM codes 250.20 or 250.22), using a national administrative database. Cases were classified into four seasons according to date of admission. The authors compared the occurrence, length of stay, in-hospital mortality and Charlson comorbidity index and its factors.
RESULTS: A total of 6596 hospitalization episodes were included. The authors found that admissions occurred more in winter, being 23% more common. No seasonal statistically significant differences were found considering the other variables.
CONCLUSIONS: There is an increased occurrence of this acute metabolic complication during the winter in patients with type 2 diabetes. These results should be taken into account by the family physician when planning surveillance to this risk group.
Copyright © 2019 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Diabetes mellius; Hospital administrative data; Hyperosmolar hyperglycemic state; Seasonal variation

Year:  2020        PMID: 31937492     DOI: 10.1016/j.pcd.2019.12.011

Source DB:  PubMed          Journal:  Prim Care Diabetes        ISSN: 1878-0210            Impact factor:   2.459


  1 in total

1.  Response to winter pressures in acute services: analysis from the Winter Society for Acute Medicine Benchmarking Audit.

Authors:  Catherine Atkin; Thomas Knight; Chris Subbe; Mark Holland; Tim Cooksley; Daniel Lasserson
Journal:  BMC Health Serv Res       Date:  2022-01-02       Impact factor: 2.655

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.